IER2 and neoplasm: Given CAFs' genetic uniformity and lower drug resistance compared to tumor cells,[36] these findings may lay the foundation for developing future therapeutic strategies by targeting ERS‐CAF through interventions with IER2 blockade or ERS inhibitors.